MONTRÉAL, Dec. 18, 2021 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (the “Company” or “Relevium”) (TSXV: RLV) is providing an update to its previously disclosed management cease trade order ("MCTO"), announced on November 1, 2021, in respect of the audited annual financial statements and corresponding management's discussion and analysis for the year ended June 30, 2021, including the CEO and CFO certifications (collectively, the “Annual Financial Filings”) that were not filed by the required filing deadline of October 28, 2021 (the “Filing Deadline”).
BI-WEEKLY MCTO UPDATE As previously disclosed, the Annual Financial Filings were not filed on or before the Filing Deadline due to audit resource scheduling and availability required to complete the financial statements and disclosures.
The Company is working expeditiously on the steps required to complete the Annual Financial Filings and expects to be able to file the Annual Financial Filings by January 31, 2022. The Company will provide updates as further information relating to the Annual Financial Filings becomes available.
The MCTO will be in effect until the Annual Financial Filings are filed and requires that the Annual Financial Filings be filed on or before January 31, 2022.
Until the Annual Financial Filings are filed, the Company will issue bi-weekly default status reports in accordance with National Policy 12-203 - Management Cease Trade Orders. The Company intends to satisfy the provisions of the Alternative Information Guidelines during the period it remains in default of the filing requirements. The Company confirms that there have been no material business developments or other material information relating to its affairs as of the date of this news release that have not been generally disclosed.
Yesterday, on December 16, 2021, the Company announced that in the month of December it secured two PPE contracts valued at CAD$11million and CAD$5 million respectively to supply a total a total of 180 million medical grade nitrile gloves. The Company also announced that on December 15, 2021, the Company delivered 127.5 million medical grade nitrile gloves, representing 100% of the first contract for a total value of CAD$11M. The Company expects to deliver the second contract in the month of January 2022.
Relevium is pleased to announce the out of court settlement between the Company and Weedsense Inc. On October 16, 2019, the Company signed an SPA which was not a final contract between the parties but rather the framework of a contract to be completed once the suspensive condition consisting of a regulatory approval of the transaction was fulfilled.
The Company and Weedsense have agreed to settle their dispute concerning the proceedings out of court in shares for a total amount of $75,000 payable in common shares of the Company with a deemed price of the higher of either a 10-day VWAP prior to issuance of the shares or $0.02.
This transaction is subject to the approval of the TSX Venture Exchange, which was submitted and is pending review.
About Relevium Technologies Inc. Relevium is a publicly traded Company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition, and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical Company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions, or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbour.
On Behalf of the Board of Directors RELEVIUM TECHNOLOGIES INC. Aurelio Useche President and CEO
For more information about this press release: Tel: +1.888.528.8687 RELEVIUM TECHNOLOGIES INC Email: investors@releviumcorp.com Website: www.releviumtechnologies.com Like us on Facebook Follow us on Twitter Follow us on LinkedIn
After revealing a new sedan last week, rumors are swirling around the EV maker's next big announcement.
Semiconductor giant Advanced Micro Devices (NASDAQ: AMD) stock is up a solid 5.7% as of 2:05 p.m. ET Monday -- the first trading day after the Christmas break. All year long, companies that build things that need semiconductors to run them -- which, at this point in history, means everything from PCs to cellphones to cars to kids' toys -- have struggled to get enough semiconductors to manufacture all the products that their customers want to buy. On the one hand, constrained chip supplies mean semiconductor makers can charge more money for their chips -- but only if they have enough manufacturing capacity to make those chips in the first place.
The Santa Claus rally is off to the best start in over 20 years and historically that bodes well for the entire seasonal period, Dow Jones data show.
Apple (NASDAQ: AAPL) shareholders beat the market on Monday as the stock rose 2% by 3:30 p.m. ET compared with a 1% rise in the S&P 500. Apple stock participated in a rally for tech giants that included well-known growth names like Meta Platforms, Nvidia, and Tesla, which all beat the market on Monday. The tech-heavy Nasdaq index was up 1.2% by late Monday compared with a 1.1% boost in the S&P 500.
S3 Partners Managing Director Ihor Dusaniwsky joins Yahoo Finance Live to review the 2021 performances of notable meme and short seller stocks.
Innovation stocks have entered “deep value territory,” Wood says.
On Dec. 16, high-end electric pickup and SUV maker Rivian Automotive (NASDAQ: RIVN) reported its first-ever quarterly results since going public through its recent IPO. The company delivered 11 electric vehicles (EVs) in total during the third quarter of 2021, bringing in approximately $1 million in revenue. Meanwhile, its market capitalization (market cap) was a princely $100 billion at the time of the quarterly release.
Nvidia GPUs power self-driving cars and cloud gaming, with the chip giant also expanding fast into the metaverse. Is Nvidia stock a buy?
If you have $100 at the ready not needed for bills or emergencies and a brokerage that allows fractional share purchases, you have enough to buy into the following pair of no-brainer stocks right now. Palantir Technologies (NYSE: PLTR) is the Liam Neeson of data analytics stocks: It has a very particular set of skills that were acquired over a very long career. The U.S. military is also a prime customer, using Palantir's technology to coordinate millions of troops around the world.
PayPal Holdings (NASDAQ: PYPL) is arguably the original fintech company, formed even before fintech became a word. It started back in 1998 as an organization called Confinity, but took on the moniker and premise we know as PayPal in 1999 when it allowed people to make and accept payments via email. Plenty of alternative payment platforms operate in this space now, like Square and Adyen, while more traditional players like Mastercard are inching their way into PayPal's digital-payments turf.
The oil industry hasn't been kind to dividend investors in recent years. Intense oil price volatility has impacted cash flow, forcing many producers to slash their dividends to stay afloat. The safest oil dividends right now are those paid by ConocoPhillips (NYSE: COP) and EOG Resources (NYSE: EOG).
The conditions aren't in place for a sharp stock market correction, says JPMorgan.
DraftKings is one of the top IPO stocks to watch, as gambling legalization gains steam. Here is what the fundamentals and technical analysis say about buying DKNG stock now.
China's BYD will look to top the 100,000 vehicles mark, after setting a sixth monthly EV sales record. Nio stock rose.
The dividends for such stocks are pretty much their only attraction. On the other hand, you can find dividend stocks that are anything but boring and stodgy. Here are three dividend stocks that soared more than 50% in 2021 and are still great buys.
Amazon is positioned to exit the pandemic as one of the biggest beneficiaries of accelerated digital transformation, one analyst says.
Advanced Micro Devices opened higher on Monday and almost immediately gave us the rotation we were looking for. Now, I know new all-time highs by year-end sounds like a stretch — and it won't be easy — but all we need from here is a 7% rally.
In the meantime, many are generating gushers of cash flow, which they're using to pay big-time dividends. Two lucrative income streams that aren't likely to go away anytime soon are those paid by Kinder Morgan (NYSE: KMI) and Williams Companies (NYSE: WMB). Natural gas pipeline giant Kinder Morgan currently offers a dividend yield of 7%.
Two blue-chip value stocks, a growth at reasonable price stock, a growth stock with upside potential, and a COVID-19 pandemic play make up a list of five stocks to buy for 2022.
The molecular testing company is expected to benefit from the rise in cases of the omicron COVID-19 variant.